Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced approval of its preclinical diabetes study protocol. This approval allows the Company to test its stem cell-derived human beta islets for effectiveness in reversing Type I diabetes in well-established experimental models of the disease. Positive results from such studies could further support various commercial applications of the Company’s stem cell-derived islets that are presently being developed for distribution to select non-therapeutic markets.
Dr. Tinalyn Kupfer, Senior Scientist at Vitro, said, “We are pleased to announce the approval by IACUC. This allows us to move forward with our beta islet testing program to include efforts to reverse diabetes. Together with our on-going functional characterization testing, these new studies will provide information on in-vivo functionality, thus providing important feedback regarding the status of our product. This development is an important component of our program to manufacture stem cell-derived human beta islets that are identical to those present within the pancreas.”
Vitro owns patent-pending technology for the generation and differentiation of adult stem cell lines and has applied this technology to production of beta islets from stem cell lines generated by the Company. Testing to determine reversal of diabetes may open opportunities to proceed with regulatory approval for therapeutic applications.
About Vitro Diagnostics, Inc.
Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, http://www.vitrodiag.com, has generated over 30 adult human stem cell lines from pancreatic tissues. These cell lines may have application in drug development and discovery, diabetes research and therapy. The Company also manufactures the VITROCELL™ brand of human pancreatic-derived cell lines and related products for research and commercial applications.
Safe Harbor Statement
Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written, may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as “intends,”“anticipates,” “believes,”“expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Dr. James Musick, 303-999-2130
Chief
Executive Officer
jim@vitrodiag.com
